INS and Hypoglycemia: Nevertheless, the lower risk of GLP-1, DPP4 or metformin-based treatments versus sulfonylurea and insulin-containing regimens may underpin the advantage of lower rates of hypoglycemia [26] with former ones leading to endpoint-relevant differences in other studies as well [27].